Amyotrophic Lateral Sclerosis
Conditions
Keywords
ALS
Brief summary
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.
Detailed description
All participants will receive a single injection of the study drug. During the first year of the study there will be 12 visits to the study center, including an overnight stay after dosing of at least 1 night. There will be a further 4 remote visits (telephone or video call). From Year 2-5 there will be 8 further visits. These will be every 6 months and will be either in-person at the study site or remote (telephone or video call) if needed or preferred. Throughout the 5-year observation period, there will be up to 20 study visits to complete follow-up tests and assessments and monitor the ongoing effects of the study drug.
Interventions
GENETICVTx-002
An investigational gene therapy targeting a specific protein.
DRUGPreventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
To reduce the risk of reactions caused by the study treatment, steroid medicines will be given in advance.
Sponsors
Vector Y Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All participants will receive a single injection of the study drug. The study will use 2 different dose levels of the study drug. Participants will be assigned to 1 of 2 groups: Group 1 (Low dose) or Group 2 (High dose). Each group will have 6 participants. The dose that participants receive will depend on their time of joining the study. Dosing will be staggered as a safety precaution with a safety monitoring committee review of health-related information in between each participant being dosed.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Capable of, and willing to, provide written informed consent and comply with study procedures, including visits to the study site and visit requirements 2. Male or female ≥ 18 years of age 3. Has a diagnosis of ALS according to the El Escorial criteria (Brooks, et al., 2000) (probable, laboratory results supported; clinically probable, clinically definite) 4. Confirmed absence of ALS caused by FUS and SOD1 gene mutations confirmed by laboratory tests. 5. A maximum of 18 months since first appearance of weakness (e.g., limb weakness, dysarthria, dysphagia, shortness of breath) 6. Erect (seated) SVC % predicted ≥ 80% at Screening 7. Treatment Research Initiative to Cure ALS (TRICALS) risk score between -2 and -6 at Screening 8. Has a reliable caregiver/partner/legal representative willing and able to support the participant in participation in the study and to give informed consent on behalf of the participant in the case that disease progression prevents the participant of giving consent (local legal rules will apply). 9. Treatment with riluzole and/or edaravone is allowed if treatment was started and has remained at a stable dose for at least 2 weeks (riluzole) or one treatment cycle (edaravone) before the Screening visit 10. Women of childbearing potential (WOCBP) and male participants with female partners who are WOCBP must agree to use highly effective contraception during and after the study. WOCBP cannot be pregnant or breastfeeding 11. Women of nonchildbearing potential must be post-menopausal or surgically sterile (e.g. hysterectomy, bilateral tubal ligation, ovaries removed) Key
Exclusion criteria
1. Diagnosis of a significant CNS or peripheral nervous system disease other than ALS that may be a cause for the participant's ALS symptoms or may confound study objectives 2. Spinal, cervical, or brain MRI/MRA indicating clinically significant abnormality 3. Presence of tracheostomy and feeding tube at Screening 4. Contraindications to corticosteroid use (e.g. due to osteoporosis, uncontrolled blood pressure, diabetes or cholesterol). 5\. Significant concomitant disease or condition within 6 months of Screening that could pose an unacceptable safety risk to the participant or interfere with the participant's ability to comply with study procedures, e.g. heart disease, uncontrolled diabetes, liver disease, autoimmune diseases needing strong immune-suppressing drugs, cancer, etc or a current psychiatric diagnosis. 6\. Clinically significant abnormalities in laboratory test results at Screening for example poor liver or kidney function, abnormal clotting or infections such as Hepatitis or HIV 7\. Use of blood thinners (e.g., warfarin, heparin, and novel oral anticoagulants) and being unable to safely stop them before certain study procedures. 8\. Contraindications to imaging methods MRI, MRA, CT due to claustrophobia and/or intolerance to contrast agents. 9\. Contraindications to general anaesthesia (GA) or deep sedation 10 Positive test for illegal drugs (except prescribed medications or permitted medicinal/recreational marijuana if used responsibly) 11\. Generally frail or if the Investigator deems participation in the study would not be in the best interest of the participant or is likely to prohibit further participation during the study Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs) | Over 5 years | Assessed by reviewing the nature, incidence, severity, relatedness, seriousness and outcome of treatment emergent adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies. | At month 6 and month 12 | Changes certain blood values |
Countries
Belgium, Netherlands, United Kingdom, United States
Contacts
CONTACTDr Olga Uspenskaya Chief medical Officer, VectorY Therapeutics, M.D; PhD
Outcome results
None listed